Targeted therapies for hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Medical Chemistry

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide.
• Advanced HCC has historically shown resistance to conventional cytotoxic chemotherapy, with limited survival benefits observed in numerous clinical trials over the past three decades.
• The emergence of targeted therapies marks a significant shift in HCC treatment paradigms.

Purpose of the Study:

• To review recent and ongoing therapeutic strategies for Hepatocellular Carcinoma (HCC).
• To highlight novel agents including small-molecule tyrosine kinase inhibitors and monoclonal antibodies.
• To discuss the potential of combination therapies in managing advanced HCC.

Main Methods:

• Review of recent and ongoing clinical trials and studies.
• Analysis of therapeutic agents targeting HCC, including small-molecule tyrosine kinase inhibitors and monoclonal antibodies.
• Evaluation of treatment outcomes and survival data for advanced HCC.

Main Results:

• Traditional chemotherapy has largely failed to demonstrate survival benefits in advanced HCC.
• Sorafenib has shown a survival advantage, establishing it as a new standard of care for unresectable HCC.
• Ongoing research focuses on novel targeted agents and combination therapies.

Conclusions:

• Targeted therapies, such as sorafenib, represent a breakthrough in HCC treatment.
• Further investigation into small-molecule inhibitors, monoclonal antibodies, and combination regimens is crucial.
• The landscape of HCC therapy is evolving towards more personalized and effective treatment strategies.